Durvalumab might significantly improve progression-free survival in patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) previously treated with chemoradiotherapy, according to interim results from a randomised phase 3 trial.

中文翻译：

---

Durvalumab可提高NSCLC的无进展生存期

根据一项随机3期试验的中期结果，杜鲁伐单抗可能显着改善先前接受放化疗的局部晚期不可切除的非小细胞肺癌（NSCLC）患者的无进展生存期。